AI-generated · cited to primary sources · not investment advice · How we research
Alkem Lab
Our verdict on Alkem Lab isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
R&D expenses for the quarter were 3.7%, which is slightly below the guided range but shows disciplined spending relative to the 4-5% target. (2 met across 2 tracked commitments)
“So I think it's more of a phasing thing, and we expect the R&D to be within 4% to 5% -- and I think we should get them.”
The company reported an EBITDA margin of 22.2% for Q3 FY26, which is significantly higher than the full-year guidance range. (2 exceeded, 1 revised, 1 met, 1 missed across 5 tracked commitments)
“And even from the EBITDA guidance perspective, I see somewhere between 19.5% to 20% should be our EBITDA for the full year.”
U.S. CDMO plant expected to reach breakeven in 12 to 18 months. — target: Breakeven
“12 to 18 months. It has just started operational in this quarter. And then 12 to 18 months, we should be reaching the breakeven.”
Management expects to file for Denosumab (Prolia/Xgevia) biosimilars in the U.S. market in approximately 1.5 years. — target: 1.5 years (+4 more commitments)
“So, we will start our filing even for the U.S. market, maybe in 1.5 years, we will file for U.S.”
Acquisition of a majority stake in Occlutech Holding AG to enter the Cardiovascular business. — target: 51–55% stake (+1 more commitment)
“On February 13, 2026, Alkem MedTech announced that it has executed a binding term sheet for a strategic investment that will result in the acquisition of a 51–55% stake in Occlutech Holding AG... It is expected that the acquisition would be completed after the regulatory approvals are obtained by June 2026.”
See the full cited Management analysis of Alkem Lab
How durable is the business?
Alkem is successfully outperforming the market in chronic and sub-chronic therapy areas like Anti-Diabetics and Neuro/CNS, strengthening its brand moat. (1 expanding)
“our chronic business as far as branded generic business is concerned. We are close to 22% of our business is from chronic and which is if you see our last 3- or 4-years trend, every year, we are improving it internally by at least 1%.”
Alkem continues to outperform the market in chronic and sub-chronic segments like Anti-Diabetics (1.4x market growth) and Neuro/CNS (1.2x market growth). (5 expanding)
“We have outperformed the IPM across seven key therapies, namely GI... Anti-Diabetics at 1.4x, Neuro/CNS at 1.2x and Respiratory, 1.4x of the market.”
Alkem is aggressively expanding its brand moat by moving into high-value MedTech segments like Orthopedics and Cardiovascular, shifting from a pure-play pharma company to a diversified healthcare technology provider. (1 expanding)
“Alkem Laboratories foray into MedTech space as natural progression for expansion... High entry barriers create a defensible and resilient competitive position”
The domestic business continues to expand, outperforming the Indian Pharmaceutical Market (IPM) by 100-150 basis points. Alkem has achieved the #1 rank in the Acute segment and #2 in new product launches. (2 expanding, 1 stable)
“our number of MRs at a group level is around 14,500... We are at 18% to 19% kind of attrition currently and which has been a substantial reduction from the previous years and much lower than the industry average”
The domestic business continues to expand, outperforming the Indian Pharmaceutical Market (IPM) growth of 8.5% with a 9.7% growth rate, driven by strong volume growth. (5 expanding across 1 engine)
“In Q4, our total revenue from operations was INR36,033 million... India sales were INR23,245 million with a Y-o-Y growth of 8.8%.”
See the full cited Business Model analysis of Alkem Lab
Where does growth come from?
The company is maintaining a steady pace of US regulatory filings and approvals, which provides visibility for future product launches despite current US pricing pressure. (1 steady, 2 new trend across 3 signals, 1 leading indicator)
“our expected launch is around September or October, somewhere around that time. And it's a limited player launch.”
Alkem is demonstrating strong market share gains in key focus therapies, outperforming the Indian Pharmaceutical Market (IPM) by 120 basis points in Q1FY26. (1 new trend across 1 signal, 1 leading indicator)
“Occlutech is one of our biggest investment in last 10 years... We want to first actually integrate Occlutech into our Alkem MedTech business, and that itself will take, say, another 12 months to do it.”
Alkem maintains a massive field force of over 12,500, which is a steady pillar of its domestic market leadership. (4 steady, 1 accelerating across 5 signals)
“our number of MRs at a group level is around 14,500... part of that addition is on the chronic side because that's where we see the growth opportunity”
R&D spending has slightly decelerated as a percentage of revenue compared to the previous year, though absolute spending remains significant to support new filings like the first BLA. (2 decelerating, 3 steady across 5 signals)
“annual spend for -- it will be within the range of 4% to 5% only. Even this year, we have been at 4.2%.”
Rising costs for raw materials (APIs) and shipping are acting as a drag on the company's profit growth. — Logistics and API Costs: Steady pressure
“current geopolitical environment and evolving global supply chain dynamics have resulted in increased logistics costs along with some pressure on APIs and the packaging materials.”
See the full cited Future Growth analysis of Alkem Lab
What could break the thesis?
The company is subject to government price controls in India, which limits its ability to raise prices to offset rising costs. [REGULATORY]
“What pricing risk we do to mitigate, I think nobody in the world can do that because the pricing is going by regulations which we have to follow.”
The risk is easing as the company reported a positive impact of 0.8% to 0.9% on gross margins due to lower API prices. (1 easing, 2 intensifying, 1 high-severity)
“the current geopolitical environment and evolving global supply chain dynamics have resulted in increased logistics costs along with some pressure on APIs and the packaging materials.”
EASING. US sales grew significantly by 28.0% YoY, driven by high-value launches like Sacubitril/Valsartan and CDMO business. The company also filed 2 ANDAs and launched 4 products this quarter to offset erosion. (1 easing, 4 stable, 1 high-severity)
“What happens is on the base business, U.S. as a market is a value erosion that we see over a period of time.”
The risk is intensifying in the short term as the company expects losses of INR 40-50 crores per year for FY26 and FY27 before breaking even in FY28. (3 intensifying, 2 easing)
“And I would like to place on record that Dr. Vikas is going to now kind of proceed from Alkem and he's done a fantastic job, and he will be missed.”
STABLE. While the document does not provide specific profit/loss for Enzene, the company continues to invest, filing its first BLA (Biologics License Application) in Q1FY26, indicating the facility is operational but still in the high-spend phase. (2 stable, 1 easing)
“So, the pricing pressures for everyone, we'll figure it out how it settles.”
See the full cited Risk analysis of Alkem Lab
Read the full thesis on Alkem Lab
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.